Jason Porter, MD
Hematology & Oncology · Germantown, TNNPI 1780927244
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 17.5%. Reporting peaked in 2023 at $301,425 and has fallen 79.5% since, to $61,716 in 2025. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 918 payments — averaging $823.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$132K
- Regeneron Healthcare Solutions, Inc.$119K
- Jazz Pharmaceuticals Inc.$96K
- Regeneron$51K
- G1 Therapeutics, Inc.$47K
- EMD Serono, Inc.$44K
- plus $267K from 43 others
Across 166 payments — averaging $6504.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mirati Therapeutics, Inc.$857K
- Genentech, Inc.$114K
- Regeneron$74K
- Daiichi Sankyo Inc.$35K
- Merck$500
What the payments were for
- Consulting fees$245,84033%
- Speaking & faculty fees$413,04855%
- Travel & lodging$72,01610%
- Food & beverage$24,3503%
- Education$2920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$166,276
- OPDIVO$97,865
- ZEPZELCA$94,172
- COSELA$46,207
- KRAZATI$33,934
- EXKIVITY$25,329
- Tepmetko$22,538
- TAGRISSO$14,880
- IMFINZI$14,366
- LUMAKRAS$9,856
- Trodelvy$8,630
- TABRECTA$8,605
- OPTUNE LUA (NOVOTTF-200T)$8,424
- KEYTRUDA$7,339
- ALUNBRIG$6,675
- TECENTRIQ$6,098
- RYBREVANT$5,643
- MEKINIST$4,808
- RETEVMO$3,361
- LORBRENA$3,240
How this compares
$755,546 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 21 | $341,340 |
| LibtayoCemiplimab-Rwlc | 28 | $273,647 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $174,855 |
| TafinlarDabrafenib Mesylate | 11 | $161,049 |
| Everolimus | 12 | $100,770 |
| EliquisApixaban | 92 | $68,182 |
| Abiraterone Acetate | 13 | $34,988 |
| XareltoRivaroxaban | 39 | $33,715 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $20,068 |
| Pemetrexed Disodium | 18 | $4,970 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 143 | $3,777 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 100 | $2,344 |
| Prochlorperazine Maleate | 133 | $1,644 |
| Oxycodone Hcl | 65 | $1,422 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $35,761 | $341,34021 claims |
| NovartisMekinist, Tafinlar | $13,424 | $335,90422 claims |
| Regeneron Healthcare Solutions, Inc.Libtayo | $118,512 | $273,64728 claims |
| PfizerEliquis | $7,073 | $68,18292 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $344 | $34,98813 claims |
| Johnson & JohnsonXarelto | $5,872 | $33,71539 claims |
| GSKTrelegy Ellipta | $2,259 | $20,06828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Germantown
- Axel GrotheyGermantown$172K
- Bradley SomerGermantown$163K
- Gang TianGermantown$53K
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.